Asia-Pacific Proteomics Market Research Report: Forecast (2023-2028)

Market Definition

Proteomics, a branch of molecular biology, is concerned with the extensive examination of proteins found in a cell, tissue, organism, or biological system. The goal of proteomics is to comprehend the structure, function, interactions, and changes of all the proteins generated by an organism (the proteome). By studying the proteome, one can gain a deeper understanding of cellular processes, protein-protein interactions, and the underlying mechanisms of diseases.

Market Insights & Analysis Asia-Pacific Proteomics Market (2023-28):

The Asia-Pacific Proteomics Market is estimated to grow at a CAGR of around 7.8% during the forecast period, i.e., 2023-28. The demand for proteomics services has depicted substantial growth due to several factors, including the increasing need for new drug development & the expansion of healthcare research infrastructure. The prevalence of various communicable & non-communicable diseases has led to a higher need to develop new drugs.

Governments across countries like China, India, etc., have been increasingly accepting the importance of developing new drugs to address potential health threats, resulting in increased investment in R&D. This emphasis on drug development necessitated a higher requirement for proteomics services, as they play a crucial role in drug discovery & development, by providing an understanding of protein targets. Consequently, the requirement for proteomics services in the field of novel drug development has been steadily increasing & is expected to continue growing in the foreseeable future with rising investments in research & development.

Moreover, the expanding demand for personalized medicine among patients & healthcare professionals after the rising incidence of chronic diseases, including cancer & diabetes, assisted the growth of the proteomics services market. For many disorders, personalized medicine offers the potential to find more efficient & focused treatments, leading to better patient outcomes.

Hence, with the developments in genomics, proteomics, and other molecular technologies, examining a person's genetic makeup & finding personalized medicines became quite accessible. Thus, consumers became more interested in personalized medicine and were ready to pay for procedures catered to their particular requirements & genetic makeup. Hence, with the rising need for personalized medicines, the need for proteomics also escalated, as it is required to determine the ideal dose & dosing protocol based on a patient's unique proteomic makeup.

Furthermore, various chronic diseases such as cancer, neurological disorders, and gastrointestinal & cardiovascular issues have been prevailing in recent years, owing to physical inactivity, sedentary lifestyle, hormonal changes, etc. Therefore, the demand for proteomics for diagnoses-based research has increased, which has been supporting the market progression.

In line with this, many companies have invested in proteomics technology which would expedite the process by achieving technological innovation. For instance,

• In 2023, New Holding, a leading life-sciences investment company, announced its investment of USD40 million in Evosep to standardize proteomics for clinical purposes.

Consequently, the rising disease incidences & investment activities toward proteomics are further expected to continue in the coming years. These investments would lead to advancements in technology to expedite & improve results, which would subsequently improve the expansion of the Asia-Pacific Proteomics Market in the forecast years.

Asia-Pacific Proteomics Market Driver:

Rising Need for New Drug Development Augmented the Demand for Proteomics Services – The rising prevalence of chronic diseases such as cancer, arthritis, chronic obstructive pulmonary disease, etc., across APAC, has been propelling pharmaceutical companies & biotech companies like Takeda, Pfizer, etc., to advance their research & development of new drugs & therapies.

As a result, the demand for proteomics services has increased since these testing services were used at various stages of drug development, such as preclinical testing, clinical trials, and others. Also, in recent years, to expedite the proteomics process various key technological developments have been observed, such as the inclusion of orbitrap mass spectrometry & protein microarrays. For instance:

• In 2022, Thermofisher Scientific Inc. launched Q Exactive UHMR Hybrid Quadrupole-Orbitrap mass spectrometers, the first time equipped with charge detection capabilities, allowing direct mass determination of hundreds to thousands of individual ions in a single spectrum.

Moreover, advancements in proteomics have expanded the scope to develop novel therapeutic therapies in recent years. As a result, biotechnology companies like Merck, GE Healthcare, etc., are increasingly investing in the research and development of drugs, as well as adopting new technologies in proteomics. These investments and technological advancements are expected to accelerate the market growth of proteomic services in the forecast years.

Asia-Pacific Proteomics Market Opportunity:

Biomarker Discovery & Validation to Emerge as a Key Opportunity Area for Proteomics Testing – Biomarkers are measurable indicators that provide valuable information about normal or pathological processes, treatment response, and disease progression. Proteomics plays a crucial role in identifying, validating, and utilizing these biomarkers for various clinical applications, presenting significant growth opportunities in the field.

In order to harness the potential of biomarker identification, several biotechnology companies like Novo Nordisk & Biorad are making significant investments in proteomics technology to offer personalized biomarker therapy to patients. For instance:

• In 2023, Novo Holdings invested USD 40 million in Evosep, a proteomics technology company, to improve the quality of life and patient care by leveraging the power of LC-MS for drug discovery and developing protein-based clinical diagnostics that involve multiple protein biomarkers.

Furthermore, the integration of other omics technologies with proteomics holds tremendous potential in enhancing the capabilities of identifying & treating complex diseases. This integration creates a vast array of opportunities for proteomics service providers & contributes to the expansion of the market in the years to come.

Asia-Pacific Proteomics Market Challenge:

Complexity in Handling Large Volume of Data to be a Major Restraint for Market Growth – Proteomic experiments generate a substantial volume of complex data, which poses various challenges in the adoption of proteomics technology. The raw data obtained from proteomic experiments, such as protein microarray intensities or mass spectrometry readings, underwent multiple steps to enhance their quality & reliability, including noise reduction, baseline correction, and normalization.

Therefore, the intricate nature of this process & the large amount of data involved have resulted in longer processing times & a higher risk of errors. Also, Minor Misinterpretations have been observed to show significant consequences on the accuracy & reliability of the data. Consequently, researchers have been facing difficulties in fully relying on these aspects.

Hence, these complexities in ensuring accurate protein identification impeded the widespread adoption of proteomics services in the market over the historical years. They acted as barriers to the technology's acceptance among healthcare facilities & hindered the overall development of the Asia-Pacific Proteomics Market.

Asia-Pacific Proteomics Market Trends:

Shift Towards Targeted Proteomics to Emerge as a Key Trend – The field of proteomics has witnessed a significant development with the emergence of discovery-based proteomics, leading to a growing trend towards protein profiling & targeted proteomics. Various targeted proteomics approaches, including selected reaction monitoring, parallel reaction monitoring, and sensitive quantification of specific peptides, have gained prominence.

This trend in the market has prompted companies to expand their product portfolios to meet the increasing demand for targeted proteomics services through mergers & acquisitions. For instance:

• In 2023, Biognosys launched Spectronaut® 18, which improves DIA proteomics projects' efficiency & scalability for all mass spectrometry instrument types. The company also demonstrates novel research capabilities with TrueDiscovery™ and TrueTarget™, showcasing mass spectrometry proteomics' utility for biomarker & drug discovery.

This trend has constantly been embraced by various companies such as Evotech & Roche, who are actively working towards advancing targeted proteomics & have been supporting market growth. Further, as the field continues to evolve, targeted proteomics is likely to play a key role in advancing our understanding of protein functions & interactions. This, in turn, is expected to have a significant impact on the Asia-Pacific Proteomics Market size in the coming years.

Asia-Pacific Proteomics Market (2023-28): Segmentation Analysis

The Asia-Pacific Proteomics Market study of MarkNtel Advisors evaluates & highlights the major trends & influencing factors in each segment & includes predictions for the period 2023–2028 at the global, regional, and national levels. In accordance to the analysis, the market has been further classified as:

Based on Technology:

• By Spectroscopy
  • Mass Spectroscopy
  • NMR Spectroscopy
  • CD Spectroscopy
• Chromatography
  • HPLC Chromatography
  • Affinity Chromatography
  • Supercritical Fluid Chromatography
  • Ion Exchange Chromatography
• By Electrophoresis
  • Gel Electrophoresis
  • Capillary Electrophoresis
• Protein Microarray
  • Biochip
• Microarray Instrument
  • Integrated System
  • Microarray Scanner
  • Arrayers
• Crystallography
• Surface Plasma Resonance
• Fractionation
• Others (X-Ray Crystallography, Enzyme-linked immunosorbent assay, etc.)

The Spectroscopy segment held a sizeable share in the Asia-Pacific Proteomics Market. The Spectroscopy segment held a sizeable share of the Asia-Pacific Proteomics Market. The growth of spectroscopy is attributed to various factors, such as its wide range of applications, including analyzing the mass of charged species, which allows the accurate measurement of proteins. In addition, various organizations have been focusing on the development of better & more efficient spectroscopy systems, which further enhanced the sales of new models of spectroscopy that are highly effective. For instance:

• In 2023, the Dalian Institute of Chemical Physics of the Chinese Academy of Sciences developed a glycosidic-bond-based mass spectrometry-cleavable cross-linker that would improve data analysis output a& identification accuracy.

Consequently, as more upgraded versions of spectroscopy devices would come up in the market, their sales would further amplify to receive better & more accurate results of protein concentration & to reduce errors in laboratory practices.

Based on End Users:

• Hospitals
• Clinical Laboratories
• Pharmaceuticals & Biotechnology Companies
• Academic Research Laboratories

Pharmaceutical & Biotechnology companies have held a significant share in the Asia-Pacific Proteomics Market as they undergo the majority of the trials for drug discovery. With the rapid expansion of the healthcare sector & rising instances of various communicable diseases, pharmaceutical manufacturers such as Pfizer, Moderna, Johnson & Johnson, etc., are increasingly engaging in R&D activities for effective drug development.

Hence, the rising investments have been widely promoting the expansion of the Asia-Pacific Proteomics Market among pharma & biotech companies, which is further projected to improve in the coming years as well.

Asia-Pacific Proteomics Market (2023-28): Regional Projection

Geographically, the Asia-Pacific Proteomics Market expands across:

• China
• India
• Japan
• South Korea
• Australia
• Singapore

China has emerged as a major player in the Proteomics Market, primarily due to its substantial healthcare investments by public authorities & the availability of robust infrastructure for research & development centers focused on drug development & disease testing. In 2021, China's healthcare budget reached USD1.2 trillion, accounting for 6.5% of the total GDP. This represents a 7.6% increase from the previous year, indicating a significant rise in government spending on the development of the healthcare sector.

Moreover, notable investments have been received in the proteomics industry in China, which further contributed to market growth. For instance:

• In 2022, IonPath, a provider of high-definition spatial proteomics, received strategic investment, enabling them to enhance their capabilities in discovering & developing highly targeted therapies for chronic diseases like cancer.

Hence, with the rapid expansion of the healthcare sector & a strong focus on establishing R&D infrastructure, China is expected to hold a significant share of the Asia-Pacific Proteomics Market in the forthcoming years as well.

Asia-Pacific Proteomics Industry Recent Development:

• 2022: Thermofisher Scientific Inc. showcased its latest mass spectroscopy instrument that enable biopharmaceutical & proteomics to solve analytical challenges.
• 2022: MRM Proteomics Inc. announced its partnership with the Agilent Technologies for the co-marketing agreement to provide a complete solution for quantitative protein & metabolite analysis.

Gain a Competitive Edge with Our Asia-Pacific Proteomics Market Report

1. Asia-Pacific Proteomics Market Report by MarkNtel Advisors provides a detailed & thorough analysis of market size, share, growth rate, competitive landscape, and key players. This comprehensive analysis helps businesses gain a holistic understanding of the market dynamics & make informed decisions.
2. This report also highlights current market trends & future projections, allowing businesses to identify emerging opportunities & potential challenges. By understanding market forecasts, companies can align their strategies & stay ahead of the competition.
3. Asia-Pacific Proteomics Market Report aids in assessing & mitigating risks associated with entering or operating in the market. By understanding market dynamics, regulatory frameworks, and potential challenges, businesses can develop strategies to minimize risks & optimize their operations.